| Methods |
RCT.
Double‐masked.
Multicenter (10). |
| Participants |
391 participants with OAG or OHT (65%).
20% African American.
Inclusion criteria: bilateral IOP of 23 mmHg or higher.
Exclusion criteria: use of adrenergic augmenting psychotropic drugs, topical or systemic corticosteroids, severe diabetes mellitus requiring changes in insulin dosage, aphakia, chronic ocular inflammation, severe OAG uncontrolled by concomitant administration of 2 or more drugs. |
| Interventions |
Levobunolol 0.5% twice daily.
Levobunolol 1% twice daily.
Timolol 0.5% twice daily. |
| Outcomes |
IOP.
Horizontal c/d ratio.
Incidence or progression of glaucomatous visual field defect. |
| Notes |
Allocation concealment deemed likely, based on double‐masked design.
4 years follow up.
107 drop‐outs (70 due to reasons unrelated to study medication) and 95 IOP failures: levobunolol 0.5% (4 systemic and 6 local side effects), levobunolol 1% (7 systemic and 13 local side effects), timolol (7 systemic and 3 local side effects). |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
